DK2013175T5 - p38 Map-kinase-inhibitorer - Google Patents
p38 Map-kinase-inhibitorer Download PDFInfo
- Publication number
- DK2013175T5 DK2013175T5 DK07732629.6T DK07732629T DK2013175T5 DK 2013175 T5 DK2013175 T5 DK 2013175T5 DK 07732629 T DK07732629 T DK 07732629T DK 2013175 T5 DK2013175 T5 DK 2013175T5
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitors
- map kinase
- map
- inhibitors
- kinase
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0608855A GB0608855D0 (en) | 2006-05-04 | 2006-05-04 | Inhibitors of MAP kinase enzymes |
| GB0613914A GB0613914D0 (en) | 2006-07-13 | 2006-07-13 | Inhibitors of p38 map kinase |
| PCT/GB2007/001596 WO2007129040A1 (en) | 2006-05-04 | 2007-05-01 | p38 MAP KINASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2013175T3 DK2013175T3 (en) | 2017-02-20 |
| DK2013175T5 true DK2013175T5 (da) | 2020-12-21 |
Family
ID=38268953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07732629.6T DK2013175T5 (da) | 2006-05-04 | 2007-05-01 | p38 Map-kinase-inhibitorer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8044211B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2013175B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5340918B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101429780B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102942520B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007246869B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0711310B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2650970C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1118518T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2013175T5 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2605727T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE033281T2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ573348A (cg-RX-API-DMAC7.html) |
| PT (1) | PT2013175T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007129040A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EA017198B1 (ru) * | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
| CN101842361B (zh) | 2007-06-27 | 2013-06-05 | 阿斯利康(瑞典)有限公司 | 吡嗪酮衍生物及其在治疗肺病中的用途 |
| JP2011503042A (ja) * | 2007-11-07 | 2011-01-27 | クロマ セラピューティクス リミテッド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| EP2245012B1 (en) | 2008-02-29 | 2013-07-03 | Chroma Therapeutics Limited | Inhibitors of p38 map kinase |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| BR112015008167B1 (pt) | 2012-10-17 | 2020-11-17 | Macrophage Pharma Limited | composto, composição farmacêutica, métodos para a inibição da atividade de uma enzima quinase map p38, para o tratamento ou a prevenção de doença autoimune ou inflamatória em um indivíduo, e para o tratamento, a melhoria ou a redução da incidência de doença proliferativa de células em um indivíduo, uso de composto, e, ácido |
| GB201306901D0 (en) * | 2013-04-16 | 2013-05-29 | Chroma Therapeutics Ltd | Combination |
| WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0308429A (pt) * | 2002-03-14 | 2005-01-11 | Bayer Healthcare Ag | Aroilpiridinonas monocìclicas como agentes antiinflamatórios |
| PL1877098T3 (pl) * | 2005-05-05 | 2013-09-30 | Glaxosmithkline Ip Dev Ltd | Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy |
| EP2245012B1 (en) * | 2008-02-29 | 2013-07-03 | Chroma Therapeutics Limited | Inhibitors of p38 map kinase |
-
2007
- 2007-05-01 WO PCT/GB2007/001596 patent/WO2007129040A1/en not_active Ceased
- 2007-05-01 CN CN201210457450.4A patent/CN102942520B/zh not_active Expired - Fee Related
- 2007-05-01 DK DK07732629.6T patent/DK2013175T5/da active
- 2007-05-01 AU AU2007246869A patent/AU2007246869B2/en not_active Ceased
- 2007-05-01 JP JP2009508455A patent/JP5340918B2/ja not_active Expired - Fee Related
- 2007-05-01 PT PT77326296T patent/PT2013175T/pt unknown
- 2007-05-01 CA CA2650970A patent/CA2650970C/en not_active Expired - Fee Related
- 2007-05-01 ES ES07732629.6T patent/ES2605727T3/es active Active
- 2007-05-01 KR KR1020087029538A patent/KR101429780B1/ko not_active Expired - Fee Related
- 2007-05-01 HU HUE07732629A patent/HUE033281T2/en unknown
- 2007-05-01 US US12/299,333 patent/US8044211B2/en not_active Expired - Fee Related
- 2007-05-01 EP EP07732629.6A patent/EP2013175B9/en not_active Not-in-force
- 2007-05-01 NZ NZ573348A patent/NZ573348A/en not_active IP Right Cessation
- 2007-05-01 BR BRPI0711310A patent/BRPI0711310B8/pt not_active IP Right Cessation
-
2017
- 2017-01-02 CY CY20171100002T patent/CY1118518T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102942520A (zh) | 2013-02-27 |
| CA2650970C (en) | 2014-09-16 |
| CA2650970A1 (en) | 2007-11-15 |
| BRPI0711310B1 (pt) | 2020-12-15 |
| BRPI0711310A2 (pt) | 2011-12-06 |
| ES2605727T9 (es) | 2020-12-11 |
| ES2605727T3 (es) | 2017-03-16 |
| KR101429780B1 (ko) | 2014-08-18 |
| EP2013175B1 (en) | 2016-11-09 |
| HUE033281T2 (en) | 2017-11-28 |
| AU2007246869A1 (en) | 2007-11-15 |
| KR20090014187A (ko) | 2009-02-06 |
| EP2013175B9 (en) | 2020-11-11 |
| NZ573348A (en) | 2012-01-12 |
| PT2013175T (pt) | 2017-02-14 |
| DK2013175T3 (en) | 2017-02-20 |
| AU2007246869B2 (en) | 2012-10-18 |
| US20090099185A1 (en) | 2009-04-16 |
| WO2007129040A1 (en) | 2007-11-15 |
| BRPI0711310B8 (pt) | 2021-05-25 |
| EP2013175A1 (en) | 2009-01-14 |
| CY1118518T1 (el) | 2017-07-12 |
| JP2009535385A (ja) | 2009-10-01 |
| US8044211B2 (en) | 2011-10-25 |
| JP5340918B2 (ja) | 2013-11-13 |
| CN102942520B (zh) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2021013I2 (el) | Δι-αρυλ μετα-πυριμιδινο αναστολεις κινασων | |
| DK2350047T3 (da) | p38-MAP-KINASEINHIBITORER | |
| BRPI0922962A2 (pt) | inibidores de p38 map quinase | |
| DK2013175T5 (da) | p38 Map-kinase-inhibitorer | |
| CY2019009I1 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| CY2017012I2 (el) | Αναστολεις κινασης τυροσινης bruton | |
| ZA201103180B (en) | P38 map kinase inhibitors | |
| BRPI0716781A2 (pt) | Inibidores da quinase | |
| DK1704145T3 (da) | Selektive kinaseinhibitorer | |
| ATE479434T1 (de) | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine | |
| EP2040546A4 (en) | tyrosine kinase inhibitor | |
| ATE488505T1 (de) | Kinasehemmer auf hydantoinbasis | |
| BRPI0811212A2 (pt) | Inibidores de p70 quinase | |
| DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
| DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
| DK2125810T3 (da) | Mapk/erk-kinaseinhibitorer | |
| DK1778686T3 (da) | Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer | |
| EP1893607A4 (en) | CHECKPOINT KINASE INHIBITORS | |
| DK2035385T3 (da) | Inhibitorer af akt (proteinkinase B) | |
| DK2066662T3 (da) | Serinhydrolaseinhibitorer | |
| ATE493403T1 (de) | Kinaseinhibitoren | |
| DK1713805T3 (da) | Kinaseinhibitorer | |
| ATE520664T1 (de) | Tyrosinkinase-hemmer | |
| GB0608837D0 (en) | Inhibitors of MAP kinase | |
| DK2170891T3 (da) | Pyrazolopyrimidinon-kinasehæmmere |